Reaction on the Interpretation of the Hippocampus Avoidance Prophylactic Cranial Irradiation Trial in SCLC (NCT01780675).

Autor: Belderbos JSA; Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: j.belderbos@nki.nl., De Ruysscher DKM; Radiation Oncology (Maastro), School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands., De Jaeger K; Radiation Oncology, Catharina Hospital, Eindhoven, The Netherlands., Koppe F; Radiation Oncology, Institute Verbeeten, Tilburg, The Netherlands., Lambrecht MLF; Radiation Oncology, UZ Gasthuisberg, Leuven, Belgium., Lievens YN; Radiation Oncology, Ghent University Hospital, Ghent University, Ghent, Belgium., Dieleman EMT; Radiation Oncology, Amsterdam UMC-Location AMC, Amsterdam, The Netherlands., Jaspers JPM; Radiation Oncology, Erasmus MC Cancer Institute, Erasmus MC University Medical Center, Rotterdam, The Netherlands., Van Meerbeeck JP; Pulmonology & Thoracic Oncology, Antwerp University Hospital, Antwerp University, Edegem, Belgium., Ubbels F; Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Kwint MH; Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Kuenen MA; Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Deprez S; Department of Imaging and Pathology, KU Leuven, Leuven, Belgium; Leuven Cancer Institute (LKI), Leuven, Belgium., De Ruiter MB; Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Boogerd W; Neurology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Sikorska K; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Van Tinteren H; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Schagen SB; Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2021 Aug; Vol. 16 (8), pp. e63-e65.

In response to Park, et al.

Autor: van Diessen JNA; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Kwint MH; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Sonke JJ; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Belderbos JSA; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.

Publikováno v: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2020 Jun; Vol. 147, pp. 245-246. Date of Electronic Publication: 2020 Apr 04.

External validation of an NTCP model for acute esophageal toxicity in locally advanced NSCLC patients treated with intensity-modulated (chemo-)radiotherapy.

Autor: Dankers FJWM; Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands. Electronic address: frank.dankers@radboudumc.nl., Wijsman R; Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Troost EGC; Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Institute of Radiooncology - OncoRay, Dresden, Germany; Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany; German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany., Tissing-Tan CJA; Department of Radiation Oncology, Radiotherapiegroep, Arnhem, The Netherlands., Kwint MH; Department of Radiation Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Belderbos J; Department of Radiation Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., de Ruysscher D; Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands., Hendriks LE; Department of Pulmonary Diseases, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands., de Geus-Oei LF; Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands; Biomedical Photonic Imaging Group, MIRA Institute, University of Twente, Enschede, The Netherlands., Rodwell L; Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands., Dekker A; Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands., Monshouwer R; Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Hoffmann AL; Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Institute of Radiooncology - OncoRay, Dresden, Germany; Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany., Bussink J; Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.

Publikováno v: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2018 Nov; Vol. 129 (2), pp. 249-256. Date of Electronic Publication: 2018 Sep 18.

Risk factors for esophagitis after hypofractionated palliative (chemo) radiotherapy for non-small cell lung cancer.

Autor: Nieder, Carsten^1,2 (AUTHOR) carsten.nieder@nlsh.no, Imingen, Kristian S.^1,2 (AUTHOR), Mannsåker, Bård¹ (AUTHOR), Yobuta, Rosalba¹ (AUTHOR), Haukland, Ellinor^1,2 (AUTHOR)

Publikováno v: Radiation Oncology. 5/1/2020, Vol. 15 Issue 1, p1-6. 6p.

Duration of acute esophageal toxicity in concomitant radio-chemotherapy for non-small cell lung cancer with different fractionation schedules.

Autor: Socha, Joanna, Wasilewska-Teśluk, Ewa, Stando, Rafal, Kuncman, Lukasz, Kepka, Lucyna

Publikováno v: British Journal of Radiology; Dec2021, Vol. 94 Issue 1128, p1-10, 10p